1. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Issue 10297 (24th July 2021) Authors: Berdeja, Jesus G; Madduri, Deepu; Usmani, Saad Z; Jakubowiak, Andrzej; Agha, Mounzer; Cohen, Adam D; Stewart, A Keith; Hari, Parameswaran; Htut, Myo; Lesokhin, Alexander; Deol, Abhinav; Munshi, Nikhil C; O'Donnell, Elizabeth; Avigan, David; Singh, Indrajeet; Zudaire, Enrique; Yeh, Tzu-Min; Allred... Journal: Lancet Issue: Volume 398:Issue 10297(2021) Page Start: 314 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Comprehensive BCMA Expression Profiling in Adult Normal Human Brain Suggests a Low Risk of On-target Neurotoxicity in BCMA-targeting Multiple Myeloma Therapy. (April 2022) Authors: Marella, Mathieu; Yao, Xiang; Carreira, Vinicius; Bustamante, Marta F.; Clark, H. Brent; Jackson, Carolyn C.; Zudaire, Enrique; Schecter, Jordan M.; Glover, Tynisha D.; Shenton, Jacintha; Cornax, Ingrid Journal: Journal of histochemistry and cytochemistry Issue: Volume 70:Number 4(2022) Page Start: 273 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗